All In Biotech

Drug Trial Radar · NCT04366908

Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome

Prevention and Treatment With Calcifediol of COVID-19 Coronavirus-induced Acute Respiratory Syndrome (SARS)

Last checked: Nov 19, 2026Latest source record: Mar 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 517 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

517

Actual

Start

May 7, 2020

Primary completion

Apr 19, 2022

Study completion Apr 19, 2022

Sponsor

Lead sponsor
Maimónides Biomedical Research Institute of CórdobaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Junta de Andalucia; Dynamic Solutions; Faes Farma, S.A.
First posted
Apr 29, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The administration of Calcifediol in patients with COVID-19, will reduce the development of SARS and the worsening of the various phases of the syndrome. Reducing at least 25% in ICU admission and death from the process, reducing days of hospitalization, facilitating the recovery of the same, acting significantly and positively, in any of its phases throughout the natural history of illness. As a treatment with extensive experience of clinical use, safe, inexpensive, and potentially very effective, it will have a highly efficient cost-benefit impact on the prevention of SARS.

Conditions

  • SARS-CoV 2
  • COVID19
  • SARS (Severe Acute Respiratory Syndrome)
  • Cytokine Release Syndrome
  • Cytokine Storm

Interventions

  • BAT + CalcifediolDrug

    The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS) plus Calcifediol caps. 266 µg. According to the pharmacokinetics of Calcifediol evaluated in an inflammatory model, the posology will be Start: 2 capsules Days 3, 7, 14, 21, 28: 1 capsule

  • BATDrug

    The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Admission to Intensive Care UnitTime frame: At day 28.
  2. DeathTime frame: At day 28.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario Reina Sofía

    Córdoba, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.